Natural Product Target Network Reveals Potential for Cancer Combination Therapies
A body of research demonstrates examples of and synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence...
Uloženo v:
| Vydáno v: | Frontiers in pharmacology Ročník 10; s. 557 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Frontiers Media S.A
31.05.2019
|
| Témata: | |
| ISSN: | 1663-9812, 1663-9812 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A body of research demonstrates examples of
and
synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products. |
|---|---|
| AbstractList | A body of research demonstrates examples of in vitro and in vivo synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products.A body of research demonstrates examples of in vitro and in vivo synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products. A body of research demonstrates examples of in vitro and in vivo synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products. A body of research demonstrates examples of and synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products. |
| Author | Kulesz-Martin, Molly Chamberlin, Steven R. Choonoo, Gabrielle Wu, Guanming Shinto, Lynne McWeeney, Shannon Blucher, Aurora |
| AuthorAffiliation | 1 Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology , Portland, OR , United States 3 Oregon Clinical and Translational Research Institute , Portland, OR , United States 4 Department of Neurology, Oregon Health and Science University , Portland, OR , United States 5 Departments of Dermatology and Cell, Developmental and Cancer Biology, Oregon Health and Sciences University , Portland, OR , United States 2 OHSU Knight Cancer Institute , Portland, OR , United States |
| AuthorAffiliation_xml | – name: 5 Departments of Dermatology and Cell, Developmental and Cancer Biology, Oregon Health and Sciences University , Portland, OR , United States – name: 2 OHSU Knight Cancer Institute , Portland, OR , United States – name: 3 Oregon Clinical and Translational Research Institute , Portland, OR , United States – name: 1 Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology , Portland, OR , United States – name: 4 Department of Neurology, Oregon Health and Science University , Portland, OR , United States |
| Author_xml | – sequence: 1 givenname: Steven R. surname: Chamberlin fullname: Chamberlin, Steven R. – sequence: 2 givenname: Aurora surname: Blucher fullname: Blucher, Aurora – sequence: 3 givenname: Guanming surname: Wu fullname: Wu, Guanming – sequence: 4 givenname: Lynne surname: Shinto fullname: Shinto, Lynne – sequence: 5 givenname: Gabrielle surname: Choonoo fullname: Choonoo, Gabrielle – sequence: 6 givenname: Molly surname: Kulesz-Martin fullname: Kulesz-Martin, Molly – sequence: 7 givenname: Shannon surname: McWeeney fullname: McWeeney, Shannon |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31214023$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kcFvFCEUxompsbX27snM0cuu8GBYuJiYTdUmTa1mPRMG3uxSZ4cVmBr_e-lua1oTuTwC7_t98L6X5GiMIxLymtE550q_63cbm-ZAmZ5T2raLZ-SESclnWjE4erQ_Jmc539C6uNZcihfkmDNgggI_IV-vbJmSHZrrFP3kSrOyaY2lucLyK6YfzTe8RTvk5joWHEuojX1MzdKODmuJ2y6MtoQ4NqsNJrsLmF-R531V4Nl9PSXfP56vlp9nl18-XSw_XM6ckFBmqvM909o7SVtgqCwwWx_oerQgtGbcaUc7zzuJiHohO-UtKN8LLgRDD_yUXBy4Ptobs0tha9NvE20w-4OY1samEtyARnVQhZoLqZkAAA2CL_Sid0AlaNVX1vsDazd1W_SufrXO5An06c0YNmYdb41s25ZpXgFv7wEp_pwwF7MN2eEw2BHjlA1UR6EkU21tffPY66_JQya1QR4aXIo5J-yNC2U_5GodBsOoucvf7PM3d_mbff5VSP8RPrD_K_kDMaez2A |
| CitedBy_id | crossref_primary_10_1093_nar_gkab913 crossref_primary_10_3389_fphar_2022_860209 crossref_primary_10_1007_s00210_022_02270_y crossref_primary_10_1038_s41598_025_03111_7 crossref_primary_10_3390_biom10020324 crossref_primary_10_3390_ijms22031052 crossref_primary_10_1016_j_tiv_2022_105458 crossref_primary_10_32725_jab_2023_016 crossref_primary_10_3390_ijms25168920 crossref_primary_10_3390_molecules25010007 crossref_primary_10_1016_j_biopha_2021_111231 crossref_primary_10_3390_molecules25010224 crossref_primary_10_1111_cas_16248 crossref_primary_10_3390_ijms221910380 crossref_primary_10_1038_s41598_022_26984_4 crossref_primary_10_3390_molecules27155008 crossref_primary_10_1097_CAD_0000000000001616 crossref_primary_10_3390_pharmaceutics14040706 crossref_primary_10_3390_cancers15030701 crossref_primary_10_3390_pharmaceutics15061653 crossref_primary_10_1007_s12223_025_01289_x crossref_primary_10_1016_j_phymed_2025_156518 crossref_primary_10_4103_2221_1691_350176 crossref_primary_10_3390_life13091878 crossref_primary_10_1515_psr_2018_0115 crossref_primary_10_3390_antiox11101982 crossref_primary_10_3390_cancers12113096 crossref_primary_10_3390_jfb14100525 crossref_primary_10_1007_s12032_024_02386_6 crossref_primary_10_1002_ctm2_795 crossref_primary_10_1155_2021_9990020 crossref_primary_10_3390_ijms22105406 crossref_primary_10_3390_ph17070873 crossref_primary_10_1016_j_heliyon_2023_e15938 crossref_primary_10_2147_IJN_S272319 crossref_primary_10_3389_fcell_2021_738838 crossref_primary_10_3390_antiox12030591 crossref_primary_10_3390_biomedicines10030531 crossref_primary_10_1155_2022_3106363 crossref_primary_10_1016_j_lfs_2024_123097 crossref_primary_10_1016_j_procs_2024_10_236 crossref_primary_10_3390_md18070347 crossref_primary_10_1080_15422119_2022_2094274 crossref_primary_10_3390_molecules27227668 crossref_primary_10_3390_biomedicines10030713 |
| Cites_doi | 10.1093/nar/gkx1121 10.1038/nbt1338 10.1016/j.phrs.2016.10.022 10.1371/journal.pone.0078085 10.1186/gb-2010-11-5-r53 10.1093/bioinformatics/btw509 10.1093/bioinformatics/btu278 10.1080/15548627.2018.1489946 10.1038/nrd2683 10.1371/journal.pone.0062839 10.1186/1752-0509-5-S1-S10 10.1093/nar/gkv1351 10.1021/acs.jnatprod.5b01055 10.1080/10915810701464641 10.1016/j.compbiolchem.2011.04.005 10.12688/f1000research.2-144.v1 10.1371/journal.pone.0157222 10.1186/1752-0509-7-90 10.1158/1535-7163.MCT-17-0384 10.3390/cancers6031769 10.1093/nar/28.1.27 10.3389/fgene.2015.00341 10.1093/nar/gks1100 10.1101/140475 10.5936/csbj.201401003 10.1038/s41598-018-35908-0 10.1016/j.chembiol.2016.05.016 10.1016/j.chembiol.2014.08.006 10.1038/nchembio.118 10.1038/msb.2013.12 10.1038/nbt1228 10.1016/j.canlet.2016.12.010 10.1214/aos/1013699998 10.1016/j.ijgo.2016.04.012 10.1186/1471-2164-11-S3-S5 10.1016/j.cell.2011.02.013 10.1101/gad.1528707 10.1093/nar/gkt1129 10.1016/j.jconrel.2015.06.040 10.1093/nar/gku1204 10.1371/journal.pone.0093960 10.1038/cddis.2013.528 10.3389/fgene.2014.00012 10.1016/j.tips.2017.08.006 10.1038/clpt.2008.129 10.1093/nar/gkt1068 10.1101/gr.128819.111 10.1038/ncomms9481 10.1038/nbt.2284 10.1038/msb4100200 10.1049/iet-syb:20060068 10.1038/srep30750 10.1038/clpt.2010.91 10.1038/nrc3599 10.1093/bioinformatics/btq476 10.1186/1756-0381-4-10 10.1038/nrd4510 10.1016/j.cell.2017.11.009 10.1093/nar/gkv1072 10.1038/nm1009-1149 10.1039/C5MB00599J 10.1158/0008-5472.CAN-16-0097 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Chamberlin, Blucher, Wu, Shinto, Choonoo, Kulesz-Martin and McWeeney. 2019 Chamberlin, Blucher, Wu, Shinto, Choonoo, Kulesz-Martin and McWeeney |
| Copyright_xml | – notice: Copyright © 2019 Chamberlin, Blucher, Wu, Shinto, Choonoo, Kulesz-Martin and McWeeney. 2019 Chamberlin, Blucher, Wu, Shinto, Choonoo, Kulesz-Martin and McWeeney |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2019.00557 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_8b2df493469142229243797fc206298f PMC6555193 31214023 10_3389_fphar_2019_00557 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NLM NIH HHS grantid: T15 LM007088 – fundername: NCI NIH HHS grantid: R01 CA192405 – fundername: U.S. National Library of Medicine |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM ACXDI IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-8bdf199dc60521e8a21a039cfea249913c9c0bd3b6eee976b8da28df43441ed23 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 49 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000470142500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1663-9812 |
| IngestDate | Fri Oct 03 12:50:45 EDT 2025 Tue Sep 30 16:58:01 EDT 2025 Sun Aug 24 03:48:26 EDT 2025 Thu Jan 02 22:59:02 EST 2025 Sat Nov 29 05:30:30 EST 2025 Tue Nov 18 21:50:59 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | cancer synergy therapeutic targets antineoplastic drug natural product |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-8bdf199dc60521e8a21a039cfea249913c9c0bd3b6eee976b8da28df43441ed23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Edited by: Brion William Murray, Pfizer, United States Reviewed by: Marco Falasca, Curtin University, Australia; Marcello Locatelli, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy |
| OpenAccessLink | https://doaj.org/article/8b2df493469142229243797fc206298f |
| PMID | 31214023 |
| PQID | 2243486185 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8b2df493469142229243797fc206298f pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555193 proquest_miscellaneous_2243486185 pubmed_primary_31214023 crossref_citationtrail_10_3389_fphar_2019_00557 crossref_primary_10_3389_fphar_2019_00557 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-31 |
| PublicationDateYYYYMMDD | 2019-05-31 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-31 day: 31 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | B20 Harding (B18) 2017; 46 Wu (B60) 2017; 389 Law (B33) 2014; 42 Yin (B66) 2014; 9 Gu (B16) 2013; 8 Newman (B41) 2016; 79 Liu (B36) 2016; 32 Pavlopoulos (B46) 2011; 4 Ntie-Kang (B43) 2013; 8 Newman (B42) 2013; 9 Yao (B64) 2018; 14 Hanahan (B17) 2011; 144 Palmer (B44) 2017; 171 Harvey (B19) 2015; 14 Jaeger (B29) 2017; 77 B37 Awan (B3) 2007; 1 B39 Tse (B54) 2016; 135 Pearson (B47) 2017; 17 Yildirim (B65) 2007; 25 Hu (B25) 2013; 2 Nalli (B40) 2018; 8 Xia (B61) 2011; 35 Druker (B12) 2009; 15 Holohan (B21) 2013; 13 Goel (B15) 2007; 26 Sun (B51) 2015; 6 Wang (B56) 2016; 23 Cote (B10) 2015; 213 Jia (B30) 2009; 8 Li (B34) 2012; 22 Fabregat (B13) 2017; 44 Cui (B11) 2007; 3 Benjamini (B5) 2001; 29 Blucher (B6) 2017; 38 Milshteyn (B38) 2014; 21 Yang (B63) 2016; 6 Hu (B24) 2016; 11 Xue (B62) 2013; 41 Paolini (B45) 2006; 24 Tamborero (B52) 2017; 10 Wohlgemuth (B58) 2010; 26 Cheng (B9) 2016; 114 Al-Lazikani (B1) 2012; 30 B53 Hwang (B28) 2008; 84 B55 Becker (B4) 2014; 5 Li (B35) 2011; 5 Qin (B49) 2014; 42 Winterbach (B57) 2013; 7 Gilson (B14) 2016; 44 Kanehisa (B31) 2000; 28 Wu (B59) 2010; 11 Laderas (B32) 2015; 6 Peng (B48) 2014; 5 Hu (B26) 2014; 9 Sun (B50) 2010; 11 Huang (B27) 2014; 30 Housman (B23) 2014; 6 Chatr-Aryamontri (B7) 2015; 43 Zhu (B67) 2007; 21 Arrell (B2) 2010; 88 Chen (B8) 2016; 12 Hopkins (B22) 2008; 4 |
| References_xml | – volume: 46 start-page: D1091 year: 2017 ident: B18 article-title: The IUPHAR/BPS Guide to pharmacology in 2018: updates and expansion to encompass the new guide to immunopharmacology publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkx1121 – volume: 25 start-page: 1119 year: 2007 ident: B65 article-title: Drug-target network publication-title: Nat. Biotechnol. doi: 10.1038/nbt1338 – volume: 114 start-page: 128 year: 2016 ident: B9 article-title: Phytomedicine-modulating oxidative stress and the tumor microenvironment for cancer therapy publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.10.022 – volume: 8 start-page: e78085 year: 2013 ident: B43 article-title: AfroDb: a select highly potent and diverse natural product library from African medicinal plants publication-title: PLoS ONE doi: 10.1371/journal.pone.0078085 – volume: 11 start-page: R53 year: 2010 ident: B59 article-title: A human functional protein interaction network and its application to cancer data analysis publication-title: Genome Biol. doi: 10.1186/gb-2010-11-5-r53 – volume: 32 start-page: 3782 year: 2016 ident: B36 article-title: Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes publication-title: Bioinformatics doi: 10.1093/bioinformatics/btw509 – volume: 30 start-page: i228 year: 2014 ident: B27 article-title: DrugComboRanker: drug combination discovery based on target network analysis publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu278 – volume: 14 start-page: 1831 year: 2018 ident: B64 article-title: Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy publication-title: Autophagy doi: 10.1080/15548627.2018.1489946 – volume: 8 start-page: 111 year: 2009 ident: B30 article-title: Mechanisms of drug combinations: interaction and network perspectives publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd2683 – volume: 8 start-page: e62839 year: 2013 ident: B16 article-title: Use of natural products as chemical library for drug discovery and network pharmacology publication-title: PLoS ONE doi: 10.1371/journal.pone.0062839 – volume: 5 start-page: S10 year: 2011 ident: B35 article-title: Network target for screening synergistic drug combinations with application to traditional Chinese medicine publication-title: BMC Syst. Biol. doi: 10.1186/1752-0509-5-S1-S10 – volume: 44 start-page: D481 year: 2017 ident: B13 article-title: The reactome pathway knowledgebase publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkv1351 – volume: 79 start-page: 629 year: 2016 ident: B41 article-title: Natural products as sources of new drugs from 1981 to 2014 publication-title: J. Nat. Prod. doi: 10.1021/acs.jnatprod.5b01055 – volume: 26 start-page: 279 year: 2007 ident: B15 article-title: Phorbol esters: structure, biological activity, and toxicity in animals publication-title: Int. J. Toxicol. doi: 10.1080/10915810701464641 – volume: 35 start-page: 121 year: 2011 ident: B61 article-title: Do cancer proteins really interact strongly in the human protein-protein interaction network? publication-title: Comput. Biol. Chem. doi: 10.1016/j.compbiolchem.2011.04.005 – volume: 2 start-page: 144 year: 2013 ident: B25 article-title: High-resolution view of compound promiscuity publication-title: F1000Research doi: 10.12688/f1000research.2-144.v1 – volume: 11 start-page: e0157222 year: 2016 ident: B24 article-title: TarNet: an evidence-based database for natural medicine research publication-title: PLoS ONE doi: 10.1371/journal.pone.0157222 – volume: 7 start-page: 90 year: 2013 ident: B57 article-title: Topology of molecular interaction networks publication-title: BMC Syst. Biol. doi: 10.1186/1752-0509-7-90 – volume: 17 start-page: 204 year: 2017 ident: B47 article-title: Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol publication-title: Mol. Cancer Ther doi: 10.1158/1535-7163.MCT-17-0384 – volume: 6 start-page: 1769 year: 2014 ident: B23 article-title: Drug resistance in cancer: an overview publication-title: Cancers (Basel). doi: 10.3390/cancers6031769 – volume: 28 start-page: 27 year: 2000 ident: B31 article-title: KEGG: kyoto encyclopedia of genes and genomes publication-title: Nucleic Acids Res. doi: 10.1093/nar/28.1.27 – ident: B39 – volume: 6 start-page: 341 year: 2015 ident: B32 article-title: A network-based model of oncogenic collaboration for prediction of drug sensitivity publication-title: Front. Genet. doi: 10.3389/fgene.2015.00341 – volume: 41 start-page: D1089 year: 2013 ident: B62 article-title: TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis publication-title: Nucleic Acids Res. doi: 10.1093/nar/gks1100 – volume: 10 start-page: 25 year: 2017 ident: B52 article-title: Cancer genome interpreter annotates the biological and clinical relevance of tumor alterations publication-title: Genome Med. doi: 10.1101/140475 – volume: 9 start-page: e201401003 year: 2014 ident: B26 article-title: Exploring compound promiscuity patterns and multi-target activity spaces publication-title: Comput. Struct. Biotechnol. J. doi: 10.5936/csbj.201401003 – volume: 8 start-page: 17519 year: 2018 ident: B40 article-title: Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs publication-title: Sci. Rep. doi: 10.1038/s41598-018-35908-0 – volume: 23 start-page: 862 year: 2016 ident: B56 article-title: Evidence-based and quantitative prioritization of tool compounds in phenotypic drug discovery publication-title: Cell Chem. Biol doi: 10.1016/j.chembiol.2016.05.016 – volume: 21 start-page: 1211 year: 2014 ident: B38 article-title: Mining the metabiome: identifying novel natural products from microbial communities publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2014.08.006 – volume: 4 start-page: 682 year: 2008 ident: B22 article-title: Network pharmacology: the next paradigm in drug discovery publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.118 – volume: 9 start-page: 655 year: 2013 ident: B42 article-title: Construction of human activity-based phosphorylation networks publication-title: Mol. Syst. Biol. doi: 10.1038/msb.2013.12 – volume: 24 start-page: 805 year: 2006 ident: B45 article-title: Global mapping of pharmacological space publication-title: Nat. Biotechnol. doi: 10.1038/nbt1228 – volume: 389 start-page: 70 year: 2017 ident: B60 article-title: Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.12.010 – volume: 29 start-page: 1165 year: 2001 ident: B5 article-title: The control of the false discovery rate in multiple testing under dependency publication-title: Ann. Stat. doi: 10.1214/aos/1013699998 – volume: 135 start-page: 177 year: 2016 ident: B54 article-title: Patient compliance with cervical smear surveillance in a shared-care setting publication-title: Int. J. Gynaecol. Obstet doi: 10.1016/j.ijgo.2016.04.012 – volume: 11 start-page: S5 year: 2010 ident: B50 article-title: A comparative study of cancer proteins in the human protein-protein interaction network publication-title: BMC Genomics doi: 10.1186/1471-2164-11-S3-S5 – volume: 144 start-page: 646 year: 2011 ident: B17 article-title: Hallmarks of cancer: the next generation. Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 21 start-page: 1010 year: 2007 ident: B67 article-title: Getting connected: analysis and principles of biological networks publication-title: Genes Dev. doi: 10.1101/gad.1528707 – volume: 42 start-page: D1118 year: 2014 ident: B49 article-title: Therapeutic target database update 2014: a resource for targeted therapeutics publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkt1129 – ident: B55 – volume: 213 start-page: 128 year: 2015 ident: B10 article-title: Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo publication-title: J. Control. Release doi: 10.1016/j.jconrel.2015.06.040 – volume: 43 start-page: D470 year: 2015 ident: B7 article-title: The BioGRID interaction database: 2015 update publication-title: Nucleic Acids Res. doi: 10.1093/nar/gku1204 – ident: B20 – volume: 9 start-page: e93960 year: 2014 ident: B66 article-title: Synergistic and antagonistic drug combinations depend on network topology publication-title: PLoS ONE doi: 10.1371/journal.pone.0093960 – volume: 5 start-page: e1000 year: 2014 ident: B4 article-title: The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression publication-title: Cell Death Dis. doi: 10.1038/cddis.2013.528 – volume: 5 start-page: 12 year: 2014 ident: B48 article-title: Utility of network integrity methods in therapeutic target identification publication-title: Front. Genet. doi: 10.3389/fgene.2014.00012 – volume: 38 start-page: 1085 year: 2017 ident: B6 article-title: Evidence-based precision oncology with the cancer targetome publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2017.08.006 – volume: 84 start-page: 563 year: 2008 ident: B28 article-title: Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2008.129 – ident: B37 – volume: 42 start-page: D1091 year: 2014 ident: B33 article-title: DrugBank 4.0: shedding new light on drug metabolism publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkt1068 – volume: 22 start-page: 1222 year: 2012 ident: B34 article-title: The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer publication-title: Genome Res. doi: 10.1101/gr.128819.111 – volume: 6 start-page: 8481 year: 2015 ident: B51 article-title: Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer publication-title: Nat. Commun. doi: 10.1038/ncomms9481 – volume: 30 start-page: 679 year: 2012 ident: B1 article-title: Combinatorial drug therapy for cancer in the post-genomic era publication-title: Nat. Biotechnol. doi: 10.1038/nbt.2284 – volume: 3 start-page: 152 year: 2007 ident: B11 article-title: A map of human cancer signaling publication-title: Mol. Syst. Biol. doi: 10.1038/msb4100200 – volume: 1 start-page: 292 year: 2007 ident: B3 article-title: Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network publication-title: IET Syst. Biol. doi: 10.1049/iet-syb:20060068 – volume: 6 start-page: 30750 year: 2016 ident: B63 article-title: A comparative analysis of community detection algorithms on artificial networks publication-title: Sci. Rep. doi: 10.1038/srep30750 – volume: 88 start-page: 120 year: 2010 ident: B2 article-title: Network systems biology for drug discovery publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2010.91 – volume: 13 start-page: 714 year: 2013 ident: B21 article-title: Cancer drug resistance: an evolving paradigm publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3599 – volume: 26 start-page: 2647 year: 2010 ident: B58 article-title: The chemical translation service–a web-based tool to improve standardization of metabolomic reports publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq476 – volume: 4 start-page: 10 year: 2011 ident: B46 article-title: Using graph theory to analyze biological networks publication-title: BioData Min. doi: 10.1186/1756-0381-4-10 – volume: 14 start-page: 111 year: 2015 ident: B19 article-title: The re-emergence of natural products for drug discovery in the genomics era publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd4510 – volume: 171 start-page: 1678 year: 2017 ident: B44 article-title: Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy publication-title: Cell doi: 10.1016/j.cell.2017.11.009 – volume: 44 start-page: D1045 year: 2016 ident: B14 article-title: BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkv1072 – volume: 15 start-page: 1149 year: 2009 ident: B12 article-title: Perspectives on the development of imatinib and the future of cancer research publication-title: Nat. Med. doi: 10.1038/nm1009-1149 – volume: 12 start-page: 614 year: 2016 ident: B8 article-title: Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination publication-title: Mol. Biosyst. doi: 10.1039/C5MB00599J – volume: 77 start-page: 459 year: 2017 ident: B29 article-title: Quantification of pathway cross-talk reveals novel synergistic drug combinations for breast cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-0097 – ident: B53 |
| SSID | ssj0000399364 |
| Score | 2.4192924 |
| Snippet | A body of research demonstrates examples of
and
synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological... A body of research demonstrates examples of in vitro and in vivo synergy between natural products and anti-neoplastic drugs for some cancers. However, the... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 557 |
| SubjectTerms | antineoplastic drug cancer natural product Pharmacology synergy therapeutic targets |
| Title | Natural Product Target Network Reveals Potential for Cancer Combination Therapies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31214023 https://www.proquest.com/docview/2243486185 https://pubmed.ncbi.nlm.nih.gov/PMC6555193 https://doaj.org/article/8b2df493469142229243797fc206298f |
| Volume | 10 |
| WOSCitedRecordID | wos000470142500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7a0EMvpe-6aYIKJVCI2bVk63FsQkIO7eKWbdmbkPUggdYbsptALvntHUnOZreU5tKLDbaExcxI8401-gbggxFm7DgNZVMHUdZC2FIGRsuu87TpqBMq1Yz88VlMJnI2U-1aqa-YE5bpgbPgRhI7hFoxDOPS7wqVGPREsHTMqZIhrr6IetaCqbQGR7_L67wviVGYGoXzUxP5P6vIT9lEb7TmhxJd_98w5p-pkmu-5_gpPBlAI_mUB_sMHvj-Oey1mXX6ep9M7w5RLfbJHmnv-KivX8DXiUnkGqTN7K5kmrK_ySRngJNv_grR4oK082VMHcKGCGTJYTQHvM1_Yeyc1Dd8BkPrl_D9-Gh6eFIOlRRKW3O6LGXnQqWUszye1fXS0MqgiGzwBsMvVTGr7LhzrOPeewQonXSGSpQ7Q7TkHWWvYKuf9_4NEB-crxrbORtMjXPWOOMaVvuKcm-4dwWMbuWq7UAzHqtd_NQYbkRN6KQJHTWhkyYK-LjqcZ4pNv7R9iCqatUukmOnB2gyejAZfZ_JFPD-VtEaJ1PcITG9n18uNOIZVkuOGKaA11nxq0-ximIwSlkBYsMkNsay-aY_O02E3bxpIlB--z8Gvw2PozhyAsM72FpeXPodeGSvlmeLi114KGZyN80FvH65OfoN45QP1w |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Product+Target+Network+Reveals+Potential+for+Cancer+Combination+Therapies&rft.jtitle=Frontiers+in+pharmacology&rft.au=Chamberlin%2C+Steven+R&rft.au=Blucher%2C+Aurora&rft.au=Wu%2C+Guanming&rft.au=Shinto%2C+Lynne&rft.date=2019-05-31&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=10&rft.spage=557&rft_id=info:doi/10.3389%2Ffphar.2019.00557&rft_id=info%3Apmid%2F31214023&rft.externalDocID=31214023 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |